Previous Close | 2.1700 |
Open | 2.1800 |
Bid | 2.2000 x 400 |
Ask | 2.2300 x 200 |
Day's Range | 2.1700 - 2.2500 |
52 Week Range | 2.1000 - 4.3000 |
Volume | |
Avg. Volume | 489,043 |
Market Cap | 220.155M |
Beta (5Y Monthly) | 1.47 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1500 |
Earnings Date | May 01, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.75 |
Accuray Incorporated (NASDAQ: ARAY) announced today that as part of its commitment to advancing patient care the company has opened a new training center in Genolier, Switzerland, that will serve as the European education hub for radiosurgery and radiotherapy product training, and sharing of best practices and innovative techniques using the latest model Accuray CyberKnife® and Radixact® Radiation Treatment Delivery Systems and Accuray Precision® Treatment Planning System. The Genolier based cen
Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2024, ended March 31, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on May 1, 2024.
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.